<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Infarction size and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> are important determinants of <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome in humans </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001794'>Bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> are promoted by <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> which in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> is mainly characterized by extensive lymphocyte <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and dysfunction </plain></SENT>
<SENT sid="2" pm="."><plain>Pharmacological inhibition of caspases may improve <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome not only by reducing apoptotic brain damage but also by attenuating <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the effects of systemic administration of the novel, non-toxic caspase-inhibitor quinolyl-<z:chebi fb="0" ids="32861">valyl</z:chebi>-O-methylaspartyl-[-2,6-difluorophenoxy]-<z:chebi fb="0" ids="15347,51867">methyl ketone</z:chebi> (Q-VD-OPH) on <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced neuronal and lymphocyte <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, <z:hpo ids='HP_0002719'>susceptibility to infections</z:hpo>, and mortality in a murine model of <z:hpo ids='HP_0001297'>stroke</z:hpo> induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="4" pm="."><plain>Q-VD-OPH reduced ischemic brain damage and <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> in thymus and spleen, decreased susceptibility to post-<z:hpo ids='HP_0001297'>stroke</z:hpo> <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e>, and improved survival </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, Q-VD-OPH may be a promising therapeutic agent in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>